Figure 1. Mirror bar plot with prescription rates of combination therapy (statins and ezetimibe) as well as maximum dose statins at entry and discharge of cardiovascular rehabilitation (CR). The length of the columns represent the relative amount (in %) with regard to the entire cohort, green bars show Group A, orange bars represent Group B. Indication for significance = p Overall: 0.05 (indicated by *).

Figure 1. Mirror bar plot with prescription rates of combination therapy (statins and ezetimibe) as well as maximum dose statins at entry and discharge of cardiovascular rehabilitation (CR). The length of the columns represent the relative amount (in %) with regard to the entire cohort, green bars show Group A, orange bars represent Group B. Indication for significance = p Overall: 0.05 (indicated by *).

Figure 2. Alluvial plot with LDL-C at CR entry (left) and at discharge (right) for (Group A) and (Group B). The height of the columns represents the number of cases, the vertical bars visualize the target corridors of the ESC/EAS lipid guidelines 2016 and 2019 (green: <1.4 mmol/L, orange: <1–8 mmol/L). Y-Axis also shows the relative number of patients (in %) reaching the target corridors.

Figure 2. Alluvial plot with LDL-C at CR entry (left) and at discharge (right) for (Group A) and (Group B). The height of the columns represents the number of cases, the vertical bars visualize the target corridors of the ESC/EAS lipid guidelines 2016 and 2019 (green: <1.4 mmol/L, orange: <1–8 mmol/L). Y-Axis also shows the relative number of patients (in %) reaching the target corridors.

Table 1. Patient characteristics overall and stratified after discharge time period.

Table 1. Patient characteristics overall and stratified after discharge time period.

OverallGroup A Group B p[875][593] [282] Male Sex (%)712 (81)497 (84)215 (76)0.009 *Age (median [IQR])62.4 [54.9, 71.4]62.3 [54.7, 70.8]63.2 [55.4, 73.2]0.23BMI (median [IQR])26.0 [24.0, 29.0]26.0 [24.0, 29.0]27.0 [24.0, 30.0]0.074Cardiovascular Risk Factors Diabetes Mellitus (%)181 (21)120 (20)61 (22)0.72Hypertension (%)566 (65)369 (62)197 (70)0.036 *Family History for CVE (%)324 (37)209 (35)115 (41)0.12Dyslipidemia (%)532 (61)330 (56)202 (72)<0.001 *Active Smoker (%)138 (25)94 (26)44 (22)0.42Smoking History (%)563 (64)366 (62)197 (70)0.019 *Diagnosis 0.73STEMI347 (40)237 (40)110 (39) NSTEMI317 (36)213 (36)104 (37) Unstable Angina24 (3)14 (2)10 (4) CCS183 (21)127 (21)56 (20) Therapy 0.099PCI689 (79)469 (79)220 (78) CABG114 (13)83 (14)31 (11) no therapy71 (8)41 (7)30 (11)

Table 2. LDL-C levels at CR entry and at discharge overall and stratified after discharge time period.

Table 2. LDL-C levels at CR entry and at discharge overall and stratified after discharge time period.

OverallGroup A Group B p[875][593] [282] Patients with LDL-C at discharge <1.4 mmol/L (%)351 (43)232 (39)119 (53)<0.001 *Patients with LDL-C at discharge <1.8 mmol/L (%)592 (73)412 (70)180 (80)0.003 *LDL-C CR entry mmol/L (median [IQR])1.6 [1.2, 2.0]1.6 [1.2, 2.0]1.7 [1.3, 2.0]0.311LDL-C CR discharge mmol/L (median [IQR])1.5 [1.2, 1.8]1.5 [1.2, 1.9]1.4 [1.1, 1.7]<0.001 * <0.001 *0.072<0.001 *

Table 3. Quantile Regression Weights for LDL-C at CR discharge.

Table 3. Quantile Regression Weights for LDL-C at CR discharge.

Coefficient/Estimate95% Confidence IntervalpIntercept1.0[0.60, 1.4]<0.001 *Age0.0037[−0.00024, 0.0074]0.048 *Male Sex−0.049[−0.17, 0.075]0.44Hypertension0.0037[−0.078, 0.086]0.93Dyslipidaemia0.13[0.053, 0.21]0.0012 *Smoking History0.14[0.057, 0.22]<0.001 *Statin Monotherapy−0.049[−0.24, 0.14]0.61Combination-therapy−0.13[−0.37, 0.11]0.28Therapy PCI−0.0038[−0.19, 0.18]0.97Therapy CABG0.15[−0.059, 0.37]0.16Group B−0.21[−0.30, −0.12]<0.001 *Rehabilitation Duration0.0015[−0.00026, 0.0033]0.075Family History for CVE 0.010[0.016, 0.18]0.021 *